AstraZeneca Strengthens China Hand With Massive R&D Boost
This article was originally published in Scrip
Executive Summary
AstraZeneca, which unlike many of its multinational peers continues to show strong growth in China, is building on this with a large investment aimed at building capacity for the development and manufacture of pharmaceuticals in the region.